Tetrahydrocannabinol and Cannabidiol in the treatment of Parkinson's Disease, is there evidence? An integrative review
DOI:
https://doi.org/10.33448/rsd-v14i3.48448Keywords:
THC; Cannabidiol; Parkinson’s disease.Abstract
Introduction: Neurodegenerative disorders, such as Parkinson’s Disease (PD), have become a growing burden worldwide. PD is characterized by the death of dopaminergic neurons and the presence of Lewy bodies, resulting in motor symptoms. The endocannabinoid system has attracted attention due to its neuroprotective potential, especially with the use of cannabinoid compounds such as THC and CBD. Objective: To analyze the clinical use of THC and CBD in the treatment of patients with PD, investigating the effects on motor symptoms, quality of life and possible adverse effects. Methodology: An integrative literature review was performed, using articles from 2014 to 2025. Results and Discussion: The use of CBD has shown modest effects in improving quality of life and reducing anxiety, but did not significantly impact motor symptoms. The impact of CBD on sleep was positive in terms of satisfaction, but without changes in REM sleep disorders. The combination of CBD and THC, on the other hand, has produced adverse effects, such as dizziness and difficulty concentrating, without clear benefits. Studies suggest that the endocannabinoid system may modulate synaptic functions, but the long-term effects are still uncertain. Conclusion: Although CBD shows some potential to improve quality of life and reduce anxiety, its effects on motor and cognitive symptoms are inconclusive. The combination of THC and CBD should be used with caution, and more controlled research is needed to assess the long-term efficacy and safety of these substances in the treatment of PD.
References
Almeida, C. M. O., Brito, M. M. C., Bosaipo, N. B., Pimentel, A. V., Sobreira-Neto, M. A., Tumas, V., Zuardi, A. W., De Souza Crippa, J. A., Hallak, J. E. C., & Eckeli, A. L. (2023). The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson’s Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial. Cannabis and cannabinoid research, 8(2), 374–378. https://doi.org/10.1089/CAN.2021.0158
Almeida, C. M. O., Brito, M. M. C., Bosaipo, N. B., Pimentel, A. V., Tumas, V., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Eckeli, A. L. (2021). Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Movement disorders : official journal of the Movement Disorder Society, 36(7), 1711–1715. https://doi.org/10.1002/MDS.28577
Anima. (2014). Manual revisão bibliográfica sistemática integrativa: a pesquisa baseada em evidências. Grupo Anima. https://biblioteca.cofen.gov.br/wpcontent/uploads/2019/06/manual_revisao_bibliografica-sistematica-integrativa.pdf.
Augustin, S. M., & Lovinger, D. M. (2018). Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System. ACS chemical neuroscience, 9(9), 2146–2161. https://doi.org/10.1021/ACSCHEMNEURO.7B00508
Bosnjak Kuharic, D., Markovic, D., Brkovic, T., Jeric Kegalj, M., Rubic, Z., Vuica Vukasovic, A., Jeroncic, A., & Puljak, L. (2021). Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews, 2021(9). https://doi.org/10.1002/14651858.CD012820.PUB2/EPDF/ABSTRACT
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., Dos Santos, A. C., Teixeira, A. L., Hallak, J. E. C., & Crippa, J. A. S. (2014). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. Journal of psychopharmacology (Oxford, England), 28(11), 1088–1092. https://doi.org/10.1177/0269881114550355
Cooray, R., Gupta, V., & Suphioglu, C. (2020). Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Molecular neurobiology, 57(11), 4878–4890. https://doi.org/10.1007/S12035-020-02054-6
Costa, A. C., Joaquim, H. P. G., Pedrazzi, J. F. C., Pain, A. de O., Duque, G., & Aprahamian, I. (2022). Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges. Brain sciences, 12(12). https://doi.org/10.3390/BRAINSCI12121596
Crossetti, M. G. M. (2012). Revisión integradora de la investigación en enfermería el rigor científico que se le exige. Rev. Gaúcha Enferm. 33 (2), 8-9.
Domen, C. H., Sillau, S., Liu, Y., Adkins, M., Rajkovic, S., Bainbridge, J., Sempio, C., Klawitter, J., & Leehey, M. A. (2023). Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson’s Disease-Related Motor Symptoms. Movement disorders : official journal of the Movement Disorder Society, 38(7), 1341–1346. https://doi.org/10.1002/MDS.29447
Faria, S. M., de Morais Fabrício, D., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N. (2020). Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of psychopharmacology (Oxford, England), 34(2), 189–196. https://doi.org/10.1177/0269881119895536
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C. (2019). The global burden of neurological disorders: translating evidence into policy. The Lancet. Neurology, 19(3), 255. https://doi.org/10.1016/S1474-4422(19)30411-9
Gyombolai, P., Pap, D., Turu, G., Catt, K. J., Bagdy, G., & Hunyady, L. (2012). Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. Molecular and cellular endocrinology, 353(1–2), 29–36. https://doi.org/10.1016/J.MCE.2011.10.011
Hafida, E. G., Rachid, S., Halima, G., & Najib, K. (2024). CBD’s potential impact on Parkinson’s disease: An updated overview. Open medicine (Warsaw, Poland), 19(1). https://doi.org/10.1515/MED-2024-1075
Hirsch, L., Jette, N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016). The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology, 46(4), 292–300. https://doi.org/10.1159/000445751
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019). How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 87–105. https://doi.org/10.1007/S00406-019-00984-4/TABLES/3
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., Itzkovitz, S., Colonna, M., Schwartz, M., & Amit, I. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell, 169(7), 1276-1290.e17. https://doi.org/10.1016/J.CELL.2017.05.018
LeMoyne, R., Mastroianni, T., Whiting, D., & Tomycz, N. (2019). New Perspectives for Network Centric Therapy for the Treatment of Parkinson’s Disease and Essential Tremor. Smart Sensors, Measurement and Instrumentation, 31, 127–128. https://doi.org/10.1007/978-981-13-5808-1_10
Liu, Y., Bainbridge, J., Sillau, S., Rajkovic, S., Adkins, M., Domen, C. H., Thompson, J. A., Seawalt, T., Klawitter, J., Sempio, C., Chin, G., Forman, L., Fullard, M., Hawkins, T., Seeberger, L., Newman, H., Vu, D., & Leehey, M. A. (2024). Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson’s Disease: A Randomized Trial. Movement disorders : official journal of the Movement Disorder Society, 39(5), 863–875. https://doi.org/10.1002/MDS.29768
Mattos, P. C. (2015). Tipos de revisão de literatura. Unesp, 1-9. https://www.fca.unesp.br/Home/Biblioteca/tipos-de-evisao-de-literatura.pdf.
Minerbi, A., Häuser, W., & Fitzcharles, M. A. (2019). Medical Cannabis for Older Patients. Drugs and Aging, 36(1), 39–51.
https://doi.org/10.1007/S40266-018-0616-5/METRICS
Pereira, D. A., Chagas, M. J. de S., Souza, L. M. de, Malfacini, S. da S., Enes, M. de F. G., Orsini, M., & Antunes, P. de F. G. (2023). Alterations in the substantia nigra and nigrostriatal pathway in different neuroimaging techniques in Parkinson’s disease: an integrative literature review. Research, Society and Development, 12(1), e8212139591–e8212139591. https://doi.org/10.33448/RSD-V12I1.39591
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM.
Pisani, S., McGoohan, K., Velayudhan, L., & Bhattacharyya, S. (2021). Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs and Aging, 38(10), 887–910. https://doi.org/10.1007/S40266-021-00882-2/METRICS
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of business research, 104, 333-339.
Zou, S., & Kumar, U. (2018a). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences, 19(3), 833. https://doi.org/10.3390/IJMS19030833
Zou, S., & Kumar, U. (2018b). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences, 19(3), 833. https://doi.org/10.3390/IJMS19030833
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Daniel Antunes Pereira; Shara Aline Bueno Dantas; Yasmin Faria Menezes Castro Santos; Sonia Alexandra Hernandez
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
